InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-17.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by GLAXOSMITHKLINE PLC. Officer active across 4 companies, notably Innoviva, Inc.. Cumulatively, 6 disclosures have been published. Split: 0 buy · 2 sells. Total volume traded: €641.4m. Activity tracked since 20 May 2021. The latest transaction was disclosed on 20 May 2021 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations6 total
1,505 sharesCommon StockSEC:0001387131-21-007179:0
1,505 sharesCommon StockSEC:0001387131-21-007179
30,253,189 sharesCommon StockSEC:0001387131-21-006822:0
30,253,189 sharesCommon StockSEC:0001387131-21-006822
32,005,260 shares@ US$12.25100.0% of flowCommon StockSEC:0001387131-21-006039
32,005,260 shares@ US$12.2519.78% mcap100.0% of flowCommon StockSEC:0001387131-21-006039:0
6 of 6 declarations
About GLAXOSMITHKLINE PLC
GLAXOSMITHKLINE PLC is a director and insider, involved with Innoviva, Inc., Lyell Immunopharma, Inc., and CVRx, Inc.
